Journal of gastroenterology and hepatology · 2025
Long-Term Surveillance for Pancreatic Carcinoma Among Patients With Branch-Duct Intraductal Papillary Mucinous Neoplasms.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Gaeun, Jung Jisoo, Kim Junyeol, Do Jae Hyuk, Choi Yoo Shin, Lee Seung Eun, Park Hyun Jeong, Lee Eun Sun, Kim Joo Young, Kang Hyun, Lee Tae Yoon, Park Tae Young, Oh Hyoung-Chul
Аннотация
BACKGROUND: Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) are characterized by a relatively slow progression to malignant transformation. We aimed to evaluate the natural history of BD-IPMNs over 10 years, focusing on clinical changes associated with malignancy and identifying predisposing factors.
METHODS: This retrospective cohort study included 308 patients with BD-IPMN monitored for up to 10 years to evaluate the development of pancreatic carcinoma.
RESULTS: The cohort comprised 308 patients with a median follow-up of 67.2 months (range: 6-234). Of these, 197 had long-term follow-up data (≥ 5 years). At 5 years, the cumulative incidence of pancreatic carcinoma was 2.1%, including 0.7% for IPMN-derived invasive carcinoma and 1.4% for de novo pancreatic ductal adenocarcinoma (PDAC). At 10 years, the cumulative incidence increased to 5.5%, with 2.7% for IPMN-derived carcinoma and 2.9% for de novo PDAC. In multivariate analysis, cyst wall thickening (odds ratio [OR]: 23.471; 95% confidence interval [CI]: 5.617-98.072; p < 0.001) and rapid cyst growth (OR: 9.761; 95% CI: 1.145-82.431; p = 0.037) were independently associated with carcinoma. In separate analyses, cyst wall thickening was the only factor independently associated with both IPMN-derived invasive carcinoma (OR: 41.765; 95% CI: 3.992-436.943; p = 0.002) and de novo PDAC (OR: 10.000; 95% CI: 1.570-63.708; p = 0.015).
CONCLUSIONS: The cumulative incidence of both IPMN-derived invasive carcinoma and de novo PDAC reached 5.5% at 10 years. Cyst wall thickening was identified as an independent risk factor. Larger studies are warranted to refine risk stratification and optimize surveillance strategies.
METHODS: This retrospective cohort study included 308 patients with BD-IPMN monitored for up to 10 years to evaluate the development of pancreatic carcinoma.
RESULTS: The cohort comprised 308 patients with a median follow-up of 67.2 months (range: 6-234). Of these, 197 had long-term follow-up data (≥ 5 years). At 5 years, the cumulative incidence of pancreatic carcinoma was 2.1%, including 0.7% for IPMN-derived invasive carcinoma and 1.4% for de novo pancreatic ductal adenocarcinoma (PDAC). At 10 years, the cumulative incidence increased to 5.5%, with 2.7% for IPMN-derived carcinoma and 2.9% for de novo PDAC. In multivariate analysis, cyst wall thickening (odds ratio [OR]: 23.471; 95% confidence interval [CI]: 5.617-98.072; p < 0.001) and rapid cyst growth (OR: 9.761; 95% CI: 1.145-82.431; p = 0.037) were independently associated with carcinoma. In separate analyses, cyst wall thickening was the only factor independently associated with both IPMN-derived invasive carcinoma (OR: 41.765; 95% CI: 3.992-436.943; p = 0.002) and de novo PDAC (OR: 10.000; 95% CI: 1.570-63.708; p = 0.015).
CONCLUSIONS: The cumulative incidence of both IPMN-derived invasive carcinoma and de novo PDAC reached 5.5% at 10 years. Cyst wall thickening was identified as an independent risk factor. Larger studies are warranted to refine risk stratification and optimize surveillance strategies.